DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita (NYSE:DVA) highlighted progress in value-based kidney care on March 18, 2026, citing improved quality metrics, shared savings and scale in coordinated care.
Key points: a 9% Total Quality Score improvement, >$200 million in cumulative shared savings, and management of $5+ billion in medical costs under management, tied to better treatment starts and reduced catheter use.
Alebund Pharmaceuticals (NYSE:DVA) granted R1 Therapeutics exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China and received a substantial non-dilutive equity stake in R1.
The deal includes up to low triple‑digit millions in milestone payments, tiered royalties in the low double‑digit percent range, and a planned global Phase 2b MRCT starting later this year.
DaVita (NYSE: DVA) will participate in TD Cowen's 46th Annual Health Care Conference with CFO Joel Ackerman and VP of Investor Relations Nic Eliason in a fireside chat on March 2, 2026 at 11:50 am EST. A live webcast is available via TD Cowen with free registration.
As of Dec 31, 2025, DaVita served ~295,000 patients across 3,242 outpatient dialysis centers globally.
DaVita (NYSE: DVA) reported consolidated revenues of $3.620B for Q4 2025 and $13.643B for full-year 2025, adjusted diluted EPS of $3.40 (Q4) and $10.78 (2025), operating cash flow of $541M (Q4) and free cash flow of $1,024M (2025).
The company refinanced Term Loan A-1, issued 6.75% senior notes due 2033, repurchased 12.7M shares in 2025, and provided 2026 guidance for adjusted operating income and adjusted EPS.
Elara Caring announced a strategic investment from Ares and DaVita (DVA) to expand clinically advanced, in‑home care for complex and high‑acuity patients. The partners will co‑develop a kidney‑specific home care model and support Elara’s scale-up while Elara remains an independent company led by CEO Ananth Mohan.
The transaction is subject to customary closing conditions and regulatory approvals, with closing expected later in 2026; financial terms were not disclosed.
DaVita (NYSE: DVA) will hold its fourth quarter 2025 earnings conference call on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release fourth quarter results after market close the same day. The call will be webcast and accessible via the DaVita investor relations web page; a live dial‑in is available (U.S. 877-918-6630; international 517-308-9042) and callers should provide the password "Earnings".
Investors unable to listen live can access a replay on the company website; there will be no telephone replay.
Tolion Health AI (DVA) appointed Gregory J. Moore, MD, PhD, to its board on January 6, 2026, strengthening clinical, AI, regulatory, and global growth expertise.
Dr. Moore brings experience leading health and life-sciences teams at Microsoft and Google, board service at DaVita and Fortive, and academic and clinical credentials. Tolion highlighted its 2025 US launch of Tolion Brain Coach on the Apple App Store, recent fundraising, and US/Europe infrastructure growth. Near-term priorities include user growth, Apple Health interoperability, an Android release, Garmin integration, and partnerships with labs, health plans, and specialty providers.
DaVita (NYSE: DVA) named Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective Dec. 11, 2025. Both executives bring more than a decade of experience at DaVita and will lead people, strategy, and innovation efforts—Phillips will oversee DaVita Venture Group and corporate strategy. The appointments emphasize a people-first approach and a focus on technology-driven care transformation.
As of Sept. 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient centers worldwide, underscoring the scale behind the leadership shift.
DaVita (NYSE: DVA) said its chief financial officer, Joel Ackerman, will take part in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 11:20 am ET.
Investors can watch a live webcast via Wolfe Research with free registration. As of September 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient dialysis centers—2,662 in the United States and 585 across 14 other countries.
The company describes itself as a comprehensive kidney care provider focused on clinical quality and transforming care delivery.
DaVita (NYSE: DVA) will present six new studies at ASN Kidney Week 2025 in Houston (Nov 5–9), including an oral presentation linking GLP‑1 receptor agonist use with improved hospitalization rates in patients with end‑stage kidney disease. The studies cover dialysis modalities, middle‑molecule clearance, transplant access, and end‑of‑life care.
DaVita highlights ongoing R&D into advanced dialysis therapies and middle‑molecule removal and will staff booth #702 at the George R. Brown Convention Center. As of Sept 30, 2025, DaVita served approximately 293,200 patients across 3,247 outpatient dialysis centers (2,662 U.S.; 585 in 14 other countries).